Glutathione redox imbalance in brain disorders

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 1, 2015, Pages 89-95

  Gu, Feng ^a   Chauhan, Ved ^a   Chauhan, Abha ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; Autism; Bipolar disorder; Glutathione; N acetylcysteine; Parkinson's disease; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; BIOLOGICAL MARKER; GLUTATHIONE; GLUTATHIONE DISULFIDE; LIPOSOME; MILK PROTEIN; ANTIOXIDANT;

ALZHEIMER DISEASE; AUTISM; BIPOLAR DISORDER; BRAIN DISEASE; DEGENERATIVE DISEASE; ENZYME ACTIVITY; HUMAN; METABOLISM; METHYLATION; MITOCHONDRION; NEUROPATHOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; BRAIN; OXIDATION REDUCTION REACTION;

ANTIOXIDANTS; BRAIN; BRAIN DISEASES; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84916885693     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000134     Document Type: Review

References (58)

1. Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci 2013; 14: 21021-21044.
2. Johnson WM, Wilson-Delfosse AL, Mieyal JJ. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 2012; 4: 1399-1440.
3. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30: 42-59.
4. Frye RE, James SJ. Metabolic pathology of autism in relation to redox metabolism. Biomark Med 2014; 8: 321-330.
5. Gu F, Chauhan V, Chauhan A. Impaired synthesis and antioxidant defense of glutathione in the cerebellum of autistic subjects: Alterations in the activities and protein expression of glutathione-related enzymes. Free Radic Biol Med 2013; 65: 488-496.
6. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 2012; 37: 1681-1689.
7. Saharan S, Mandal PK. The emerging role of glutathione in Alzheimer's disease. J Alzheimers Dis 2014; 40: 519-529.
8. Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 2013; 62: 13-25.
9. Rosa AR, Singh N, Whitaker E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med 2014; 44: 2409-2418.
10. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci U S A 2007; 104: 16621-16626.
11. Weiduschat N, Mao X, Hupf J, et al. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett 2014; 570: 102-107.
12. Mason RP, Casu M, Butler N, et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat Genet 2013; 45: 1249-1254.
13. Ferreira B, Mendes F, Osorio N, et al. Glutathione in multiple sclerosis. Br J Biomed Sci 2013; 70: 75-79.
14. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron 2000; 28: 355-363.
15. Wingate M, Kirby RS, Pettygrove S, et al. Prevalence of autism spectrum disorder among children aged 8 years -autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63: 1-21.
16. Chauhan A, Gu F, Chauhan V. Mitochondrial respiratory chain defects in autism and other neurodevelopmental disorders. J Pediatr Biochem 2012; 2: 213-223.
17. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: Immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389-401.
18. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290-314.
19. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. Free Radic Biol Med 2012; 52: 2128-2141.
20. Chauhan A, Gu F, Essa MM, et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011; 117: 209-220.
21. Rose S, Melnyk S, Pavliv O, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012; 2: E134.
22. Main PA, Angley MT, O'Doherty CE, et al. The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: A systematic review and meta-analysis. Nutr Metab (Lond) 2012; 9: 35.
23. Rose S, Melnyk S, Trusty TA, et al. Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. Autism Res Treat 2012; 2012: 986519.
24. Ghanizadeh A, Akhondzadeh S, Hormozi M, et al. Glutathione-related factors and oxidative stress in autism: A review. Curr Med Chem 2012; 19: 4000-4005.
25. Alabdali A, Al-Ayadhi L, El-Ansary A. A key role for an impaired detoxification mechanism in the etiology and severity of autism spectrum disorders. Behav Brain Funct 2014; 10: 14-24.
26. Deth RC. Autism: A redox/methylation disorder. Glob Adv Health Med 2013; 2: 68-73.
27. Hodgson NW, Waly MI, Al-Farsi YM, et al. Decreased glutathione and elevated hair mercury levels are associated with nutritional deficiency-based autism in Oman. Exp Biol Med 2014; 239: 697-706.
28. Muratore CR, Hodgson NW, Trivedi MS, et al. Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autism. PLoS One 2013; 8: E56927.
29. Frye RE, Melnyk S, Fuchs G, et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013; 2013: 609705.
30. Frye RE, Delatorre R, Taylor H, et al. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl Psychiatry 2013; 3: E273.
31. Zhang C, Rodriguez C, Spaulding J, et al. Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis 2012; 28: 655-666.
32. Mandal PK, Tripathi M, Sugunan S. Brain oxidative stress: Detection and mapping of antioxidant marker 'glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using noninvasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 2012; 417: 43-48.
33. Duffy SL, Lagopoulos J, Hickie IB, et al. Glutathione relates to neuropsychological functioning in mild cognitive impairment. Alzheimers Dement 2014; 10: 67-75.
34. Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M. Beta-amyloidolysis and glutathione in Alzheimer's disease. J Blood Med 2013; 4: 31-38.
35. Hauser DN, Dukes AA, Mortimer AD, Hastings TG. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic Biol Med 2013; 65: 419-427.
36. Koo HJ, Yang JE, Park JH, et al. Alpha-synuclein-mediated defense against oxidative stress via modulation of glutathione peroxidase. Biochim Biophys Acta 2013; 1834: 972-976.
37. Kim K, Yim J. Glutathione S-transferase omega suppresses the defective phenotypes caused by PINK1 loss-of-function in Drosophila. Biochem Biophys Res Commun 2013; 437: 615-619.
38. Kim K, Kim SH, Kim J, et al. Glutathione S-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease. J Biol Chem 2012; 287: 6628-6641.
39. Wang T, Wang B. Association between glutathione S-transferase M1/glutathione S-transferase T1 polymorphisms and Parkinson's disease: A meta-analysis. J Neurol Sci 2014; 338: 65-70.
40. Kulak A, Steullet P, Cabungcal JH, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: Insights from animal models. Antioxid Redox Signal 2012; 18: 1428-1443.
41. WuJQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 200-206.
42. Moylan S, Berk M, Dean OM, et al. Oxidative and nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev 2014; 45C: 46-62.
43. Ballesteros A, Jiang P, Summerfelt A, et al. No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr Res 2013; 146: 184-189.
44. Dietrich-Muszalska A, Kwiatkowska A. Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia. Neuropsychiatr Dis Treat 2014; 10: 703-709.
45. Chitty KM, Lagopoulos J, Hickie IB, Hermens DF. The impact of alcohol and tobacco use on in vivo glutathione in youth with bipolar disorder: An exploratory study. J Psychiatr Res 2014; 55: 59-67.
46. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34: 167-177.
47. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-Acetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities. Brain Behav 2014; 4: 108-122.
48. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830: 4117-4129.
49. Cacciatore I, Baldassarre L, Fornasari E, et al. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid Med Cell Longev 2012; 2012: 240146.
50. Ross EK, Gray JJ, Winter AN, Linseman DA. Immunocal(R) and preservation of glutathione as a novel neuroprotective strategy for degenerative disorders of the nervous system. Recent Pat CNS Drug Discov 2012; 7: 230-235.
51. Marshall K. Therapeutic applications of whey protein. Altern Med Rev 2004; 9: 136-156.
52. Rose S, Frye RE, Slattery J, et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry 2014; 4: E377.
53. Ghanizadeh A, Derakhshan N. N-Acetylcysteine for treatment of autism -A case report. J Res Med Sci 2012; 17: 985-987.
54. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71: 956-961.
55. Holmay MJ, Terpstra M, Coles LD, et al. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 2013; 36: 103-106.
56. Unnithan AS, Jiang Y, Rumble JL, et al. N-acetylcysteine prevents synergistic, severe toxicity from two hits of oxidative stress. Neurosci Lett 2014; 560: 71-76.
57. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med 1991; 91: 131S-139S.
58. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989; 36: 127-131.